DR. DOPING

Instructions

Logo DR. DOPING

Instructions / Instruction for use: PK-Merz

I want this, give me price

Dosage form: Solution for infusions; Film coated tablets

Active substance: Amantadine*

ATX

N04BB01 Amantadine

Pharmacological groups:

Dopaminomimetics

Anti-Parkinsonics

The nosological classification (ICD-10)

G20 Parkinson's disease: A trembling paralysis; Idiopathic Parkinsonism; Parkinson's disease; Symptomatic Parkinsonism

G21 Secondary Parkinsonism: Medicinal Parkinsonism; Parkinsonism; Parkinsonism symptomatic; Disorders of extrapyramidal system; Parkinson's Syndrome

G25 Other extrapyramidal and motor disorders: extrapyramidal disorders; Disorders of extrapyramidal system; Cerebellar movement disorders; Extrapyramidal hyperkinesis; Pyramidal spastic paresis; The defeat of the pyramidal system; The defeat of the extrapyramidal system

G53.0 Neuralgia after shingles (B02.2 +): Postherpetic neuralgia; Postherpetic neuralgia in adults

Composition and release form

Tablets, coated with a coating.

Amantadine sulfate 100 mg

In a planar cell pack of 10; In a pack of cardboard 3 packs.

Solution for infusions 500 ml

Amantadine sulfate 200 mg

In PE bottles of 500 ml; In a box of 2 or 10 bottles.

Pharmachologic effect

Mode of action - antiparkinsonian, neuroprotective.

Pharmacodynamics

Increases the excretion of dopamine from the neuronal depot and inhibits its reverse neuronal capture, stimulates dopaminergic transmission. It inhibits the generation of impulses in the motor neurons of the central nervous system.

Indications of the drug PK-Merz

Parkinson's disease (rigidity, tremor, hypokinesia);

Parkinsonism (intensive primary treatment in severe and life-threatening cases, including during akinetic crises);

Extrapyramidal disorders caused by the administration of neuroleptics or other drugs;

Neuralgia with shingles.

Contraindications

Hypersensitivity;

glaucoma;

prostate adenoma;

Thyrotoxicosis;

epilepsy;

Psychomotor agitation; The state of the predilion or delirium; Psychoses in the anamnesis;

Acute and chronic diseases of the liver and kidneys;

Pregnancy (I trimester);

breast-feeding.

Application in pregnancy and breastfeeding

Contraindicated in the first trimester of pregnancy. At the time of treatment should stop breastfeeding.

Side effects

From the nervous system and sensory organs: mental disorders, accompanied by visual hallucinations, motor or mental arousal, dizziness, sleep disorders, decreased visual acuity (very rarely).

From the cardiovascular system and blood (hematopoiesis, hemostasis): heart failure, arrhythmia, tachycardia.

On the part of the intestine: dry mouth, nausea.

From the genitourinary system: urinary retention (in patients with prostate adenoma).

Other: very rarely - the appearance of bluish coloration of the skin of the upper and lower extremities.

Interaction

Strengthens the effects (including side effects) of other anti-Parkinsonian drugs; With simultaneous therapy with amantadine and levodopa, a reduction in the dose of levodopa is possible. Simultaneous reception with diuretics containing triamterene / hydrochlorothiazide can lead to a change in the concentration of amantadine in the plasma.

Dosing and Administration

Inside, after a meal. Dosage is selected individually, usually 100 mg / day for 3 days, then up to 200 mg / day with a further increase of 100 mg per week (the last day before dinner). The maximum dose is 600 mg / day.

IV, 500 ml 1-2 times a day for 3 hours at a rate of 55 drops per minute. With reduced renal function, the following dosage regimen is proposed:

Glomerular filtration rate, ml / min Dosage, mg Interval between doses, h
80–60 100 12
60–50 200 and 100 alternately Every second day
50–40 100 24
30–20 200 2 times per week
20–10 100 3 times a week
<10 200 and 100 Weekly and every second week

In severe cases, the dose may be increased by taking into account the risk assessment.

Precautionary measures

During the treatment of patients suffering from heart failure or circulatory disorders, constant medical supervision is required. For elderly patients (including those in a state of excitement, pre-divisions or delirium, etc.), it is recommended to reduce the dose. It is necessary to cancel the drug gradually to avoid a sharp exacerbation of the disease. You cannot drink alcohol during treatment. Patients should be warned that PK-Merz lowers the concentration of attention and the speed of psychomotor reactions.

Storage conditions of the drug PK-Merz

At a temperature not higher than 25 ° C

Keep out of the reach of children.

Shelf life of the drug PK-Merz

5 years.

Do not use after the expiry date printed on the package.


Previous Article
Instruction for use: Nakom